Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Antibe Partnership to Accelerate Drug Pipeline

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Nov 03, 2021 1:31am

487 Views

Post# 34080662

RE:RE:RE:Antibe Partnership to Accelerate Drug Pipeline

If ATE can move acute pain medications to chronic indications (which I get the white-label approach), why have they spent over a million dollars on liver specialists? Dan says they are prepared to spend more to find an OA solution.

Why waste time here ?

“The Company is investigating alternative dosing regimens as a potential path forward for chronic indications.”

Would this go above and beyond what’s out there now - making it the best alternative in a world of less than ideal solutions ?

mstrmnd wrote: If you have an IND/DIN for oral treatment of acute pain, it's natural progression to go to chronic pain thereafter

There's absolutely no need to do dose ranging for chronic pain pre-partnership, otherwise could burn through cash when #1 priority IND/DIN is Post-Operative Pain for Otenaproxesul

After successful Phase 2 in Post-Operative Pain, Antibe will have very successul efficacy and safety data for 2 IND/DINs in acute pain ready for partnership and Phase 3 RCTs

This is an acute pain drug company now, that can cross over into chronic pain and IBD post-partnership.

MrMugsy wrote:

mstrmnd wrote: Based on quality of data from existing studies, I would not be surprised if Antibe partnered with Big Pharma earlier than expected to accelerate entire drug pipeline

Antibe can conduct multiple Phase 3 clinical trials with their pipeline simultaneously with a pharma partner - Antibe took 7 years to get ATB-346 here, with a pharma partner, all 4 of their top patents can be accelerated into their respective markets

GLTA

That certainly is one potential angle and I'd welcome it.
But - I see a required path in order to open that up to us.

346(acute) seems to be straight forward.
352(acute) to also follow suit - but - we don't know the specific purpose intended for that drug (yet).

Then - the rest of the pipeline is what we'd call "long term" or chronic type indications (for the most part).

I think ATE needs to solve 346(chronic) before any partner would be interested in partnering on that pipeline. IBD, 340, respiratory and others ... all have the same likely issue - liver confusion.

So ... ATE is working on a hypothesis based on what they've learned (and are learning) from liver experts. Can they solve the liver confusion issue?

Therefore ...

Bring acute to market - and - show that H2S IP has value.

and

Solve chronic to open up the rest of the funnel to the end-game.

Then ... your angle is viable. IMO